Tuesday, October 4, 2022


Biotechnology News Magazine

BioInnovation Institute Announces New Venture House Program & Initial intake of 4 Innovative Companies

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its new Venture House program.

Formerly known as Creation House, the new Venture House program consists of the same 18-month long program with a risk-free convertible loan of EUR 1.3M. The change in strategy enables the BII to exclusively support the early-stage start-ups that have already benefitted from its 12-month Venture Lab program, created to support business acceleration, scientific and team development.

Following internal analysis, the BII team has determined that by leveraging the existing Venture Lab platform and offering an add-on funding opportunity, exclusively to those companies that have already spent a year at the BII and have built relationships with the team and its network, the BII will be better placed to support these companies in their next phase of growth.

Bobby Soni, Chief Business Officer, at BioInnovation Institute, said: “We are thrilled to present our new Venture House program. We have had great success in building our Venture Lab program as a solid platform for innovation and we believe that leveraging this existing platform will drive product innovation and ecosystem growth. By introducing this add-on funding opportunity, it will be even more attractive and exclusive for companies to be part of the program. We look forward to continuing to support these four innovative companies and accelerate their growth”.


In 2021, as part of the BII’s Venture Lab program that supports business acceleration, scientific development and team development, each Company received a risk-free convertible loan of EUR 500.000 plus access to labs and offices at the BII’s entrepreneurial ecosystem in the center of Copenhagen. Thus, after entering the Venture House program they have received in total of EUR 1.8M. The new companies the BII has accepted into the Venture House program are:

  • EvodiaBio is a bio-industrial company producing sustainable, natural aromas for the food and beverage industry. Its disruptive yeast-based technology enables consumers to enjoy the benefits of non-alcoholic beer without having to compromise on taste.
  • HEI Therapeutics is a digital therapeutics company developing the world’s first medical-grade home monitoring solution for patients with hypothyroidism based on state-of-the-art microfluidics, microtechnology and artificial intelligence.
  • Stimuliver is developing disruptive liver implant technology to treat critically failing liver function in humans. Many people suffer from chronic liver disease. By supporting the liver with Stimuliver’s 3D implants, it will help patients sustain critical organ function levels.
  • AMPA Medical is working in the field of ostomy care and have developed an internal solution to replace the ostomy bag. With a new and disruptive technology, Ampa wish to remove time-consuming, mental and physical obstacles related to the use of ostomy bags.

Since inception in 2018, the BII has supported 62 start-ups and projects with EUR 50 million in funding.  BII’s start-ups have in total raised more than EUR 207 million from local and international investors. Its diverse team brings venture capital, pharma and business expertise together to help early-stage companies accelerate to the next level. Recent portfolio company successes includeAdcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine